

Apixaban versus Warfarin in Patients with Atrial Fibrillation Results of the ARISTOTLE Trial

Presented on behalf of the ARISTOTLE Investigators and Committees

Sponsored by Bristol-Myers Squibb and Pfizer



Duke Clinical Research Institute

Background




- Warfarin is very effective at preventing stroke in patients with atrial fibrillation.
- Warfarin has several limitations, including drug and food interactions, a narrow therapeutic range, need for anticoagulation monitoring, and bleeding.
- Apixaban is a novel oral factor Xa inhibitor with rapid absorption, a half life of about 12 hours, and 25% renal elimination.
- Apixaban has been shown to reduce stroke and systemic embolism by 55% compared with aspirin in patients with atrial fibrillation and not suitable for warfarin.



Atrial Fibrillation with at Least One Additional Risk Factor for Stroke





Warfarin/warfarin placebo adjusted by INR/sham INR based on encrypted point-of-care testing device

Primary outcome: stroke or systemic embolism


Hierarchical testing: non-inferiority for primary outcome, superiority for primary outcome, major bleeding, death

U Duke Clinical Research Institute



Enrollment 18,201 patients, 1034 sites, 39 countries





Objectives



Primary objective

•To determine whether apixaban is non-inferior to warfarin at reducing stroke (ischemic or hemorrhagic) or systemic embolism in patients with atrial fibrillation and at least one additional risk factor for stroke.

Primary safety outcome

 Major bleeding according to the International Society of Thrombosis and Hemostasis (ISTH) definition.



Objectives and Statistics



To control the overall type I error, a pre-specified hierarchical sequential testing was performed.

- 1.The primary outcome (stroke or systemic embolism) for noninferiority (upper limit of 95% CI < 1.38 and upper limit of 99% CI < 1.44)
- 2.If met, then the primary outcome was tested for superiority3.If met, then major bleeding was tested for superiority4.If met, then all-cause mortality was tested for superiority



Methods



- The primary analyses were performed using Cox proportional hazards modeling with warfarin-naïve status and world region (North America, South America, Europe, Asia/Pacific) as strata.
- Efficacy analyses included all randomized patients (intentionto-treat) and included all events from randomization until the efficacy cutoff date (predefined as January 30, 2011).
- Bleeding analyses were "on treatment" including all randomized patients who received at least 1 dose of study drug and all events from initial receipt until 2 days after the last dose of study drug.



Apixaban and Warfarin Dosing



- Apixaban (or matching placebo) was dosed at 5 mg twice daily, or 2.5 mg twice daily for a subset of patients with 2 or more of the following criteria: age ≥ 80 years, body weight ≤ 60 kg, serum creatinine ≥ 1.5 mg/dL (133 µmol/L).
- Warfarin (or matching placebo) was dosed guided by blinded encrypted INR point-of-care device, with target INR of 2.0–3.0.



Baseline Characteristics



Characteristic	Apixaban (n=9120)	Warfarin (n=9081)
Age, years, median (25 th , 75 th %ile)	70 (63, 76)	70 (63, 76)
Women, %	35	35
Region, %		
North America	25	25
Latin America	19	19
Europe	40	40
Asia/Pacific	16	16
Warfarin naïve, %	43	43
CHADS score, mean (+/- SD)	2.1 (+/- 1.1)	2.1 (+/- 1.1)
1, %	34	34
2, %	36	36
≥ 3, %	30	30



Baseline Characteristics



Characteristic	Apixaban (n=9120)	Warfarin (n=9081)
Qualifying risk factors, %		
Age ≥75 yrs	31	31
Prior stroke, TIA, or SE	19	20
Heart failure or reduced LV EF	35	36
Diabetes	25	25
Hypertension	87	88
Renal function (Cl _{cr} ml/min), %		
Normal (>80)	41	41
Mild impairment (>50 – 80)	42	42
Moderate impairment (>30 – 50)	15	15
Severe impairment (≤ 30)	1.5	1.5



Trial Metrics




- Patients enrolled from December 2006 to April 2010
- Median duration of follow-up 1.8 years
- Drug discontinuation in 25.3% of apixaban and 27.5% of warfarin patients (p=0.001)
- Vital status at the end of the trial was missing in 380 (2.1%) patients
 - Withdrawal of consent in 199 patients
 - Loss to follow-up in 69 patients
- Median (and mean) times in therapeutic INR range among warfarin- treated patients were 66.0 (and 62.2)%.

*Rosendaal FR et al. Throb Haemost 1993;69:236–39.



Primary Outcome

Stroke (ischemic or hemorrhagic) or systemic embolism






Efficacy Outcomes



	ApixabanWarfarin (N=9120)Event Rate(N=9081)Event RateEvent Rate (%/yr)			Р	
Outcome			HR (95% CI)	Value	
Stroke or systemic embolism*	1.27	1.60	0.79 (0.66, 0.95)	0.011	
Stroke	1.19	1.51	0.79 (0.65, 0.95)	0.012	
Ischemic or uncertain	0.97	1.05	0.92 (0.74, 1.13)	0.42	
Hemorrhagic	0.24	0.47	0.51 (0.35, 0.75)	<0.001	
Systemic embolism (SE)	0.09	0.10	0.87 (0.44, 1.75)	0.70	
All-cause death*	3.52	3.94	0.89 (0.80, 0.998)	0.047	
Stroke, SE, or all-cause death	4.49	5.04	0.89 (0.81, 0.98)	0.019	
Myocardial infarction	0.53	0.61	0.88 (0.66, 1.17)	0.37	

* Part of sequential testing sequence preserving the overall type I error **U Duke Clinical Research Institute**





U Duke Clinical Research Institute

Bleeding Outcomes




Outcome	Apixaban (N=9088)	Warfarin (N=9052)		P Value
	Event Rate (%/yr)	Event Rate (%/yr)	HR (95% CI)	
Primary safety outcome: ISTH major bleeding*	2.13	3.09	0.69 (0.60, 0.80)	<0.001
Intracranial	0.33	0.80	0.42 (0.30, 0.58)	<0.001
Gastrointestinal	0.76	0.86	0.89 (0.70, 1.15)	0.37
Major or clinically relevant non-major bleeding	4.07	6.01	0.68 (0.61, 0.75)	<0.001
GUSTO severe bleeding	0.52	1.13	0.46 (0.35, 0.60)	<0.001
TIMI major bleeding	0.96	1.69	0.57 (0.46, 0.70)	<0.001
Any bleeding	18.1	25.8	0.71 (0.68, 0.75)	<0.001

* Part of sequential testing sequence preserving the overall type I error **U Duke Clinical Research Institute**




Subgroups for Stroke and Systemic Embolism (1 of 2)



Duke Clinical Research Institute

Subgroups for Stroke and Systemic Embolism



U Duke Clinical Research Institute

UITSALA CLINICAL RESEARCH CENTER

Subgroups for Major Bleeding (1 of 2)



1012)					
Characteristics	No. of Patients	Apixaban no. of eve	Warfarin ents (%/yr)	Hazard Ratio with Warfarin (95% CI)	P-value for Interaction
All Patients Prior Warfarin/VKA Status	18140	327 (2.13)	462 (3.09)	÷ [0.50
Experienced	10376 7764	185 (2.1) 142 (2.2)	274 (3.2) 188 (3.0)	<u>+</u>	0.00
Age	5455				0.64
<65 yrs ≥65 to < 75 yrs	7030	56 (1.2) 120 (2.0)	72 (1.5) 166 (2.8)	_	
≥75 yrs Sex	5655	151 (3.3)	224 (5.2)		0.08
Male Female	11747 6393	225 (2.3) 102 (1.9)	294 (3.0) 168 (3.3)		
Weight ≤60 kg	1978	36 (2.3)	62 (4.3)		0.22
>60 kg Type of Atrial Fibrillation	16102	290 (2.1)	398 (3.0)		0.75
Permanent/Persistent Paroxysmal	15361 2776	283 (2.2) 44 (1.9)	402 (3.2) 60 (2.6)	_ 	
Prior Stroke or TIA Yes	3422	77 (2.8)	106 (3.9)		0.71
No Diabetes Mellitus	14718	250 (2.0)	356 (2.9)	-	0.003
Yes No	4526 13614	112 (3.0) 215 (1.9)	114 (3.1) 348 (3.1)		
		,			
			0	.25 0.5 1 Apixaban War	

Better

Better

RESEARCH CENTER

U Duke Clinical Research Institute

Subgroups for Major Bleeding (2 of 2)



()					
Characteristics	No. of Patients	Apixaban no. of eve	Warfarin ents (%/yr)	Hazard Ratio with Warfarin (95% CI)	P-value for Interaction
All Patients	18140	327 (2.13)	462 (3.09)		
Heart Failure	_				0.30
Yes	5527	87 (1.9)	137 (3.1)		
No	12613	240 (2.2)	325 (3.1)		
CHADs Score					0.40
≤1	6169	76 (1.4)	126 (2.3)		
=2	6492	125 (2.3)	163 (3.0)		
≥3	5479	126 (2.9)	173 (4.2)		
Level of Renal Impairment				-	0.03
Severe or Moderate	3005	73 (3.2)	142 (6.4)		0,00
Mild	7565	157 (2.5)	199 (3.2)		
No impairment	7496	96 (1.5)	119 (1.8)		0.04
Apixaban Dose	000	00 (0 0)			0.21
2.5 mg BID or placebo	826	20 (3.3)	37 (6.7)	_	
5 mg BID or placebo	17314	307 (2.1)	425 (3.0)		
Geographic Region					0.16
North America	4463	106 (2.8)	137 (3.6)		
Latin America	3460	60 (2.1)	94 (3.5)		
Europe	7313	110 (1.7)	135 (2.2)		
Asia/Pacific	2904	51 (2.1)	96 (4.1)		
Aspirin at Randomization		••• (=•••/		_	0.40
Yes	5608	129 (2.7)	164 (3.7)		0,-10
No	12532	198 (1.9)	298 (2.8)		
		190 (1.9)	230 (2.0)		
				0.25 0.5 1	2

Apixaban

Better

Warfarin

Better

RESEARCH CENTER

U Duke Clinical Research Institute

Adverse Events and Liver Function Tests



N (%)	Apixaban (N=9088)	Warfarin (N=9052)
Total patients with an adverse event	7406 (81.5)	7521 (83.1)
Total patients with a serious adverse event	3182 (35.0)	3302 (36.5)
Serious adverse events reported in ≥ 1% of patients in either treatment group		
Atrial fibrillation	301 (3.3)	287 (3.2)
Pneumonia	202 (2.2)	231 (2.6)
Discontinuations due to an adverse event	688 (7.6)	758 (8.4)
ALT or AST > 3X ULN and total bilirubin > 2X ULN	30/ 8788 (0.3)	31/ 8756 (0.4)
ALT elevation		
> 3X ULN	100/ 8790 (1.1)	89/ 8759 (1.0)
> 5X ULN	45/ 8790 (0.5)	47/ 8759 (0.5)
> 10X ULN	16/ 8790 (0.2)	20/ 8759 (0.2)
> 20X ULN	8/ 8790 (<0.1)	12/ 8759 (0.1)





4 hemorrhagic

2 ischemic/uncertain type

Compared with warfarin, apixaban (over 1.8 years) prevented

- 6 Strokes
- 15 Major bleeds
- 8 Deaths

per 1000 patients treated.



Summary



- Treatment with apixaban as compared to warfarin in patients with AF and at least one additional risk factor for stroke:
- •Reduces stroke and systemic embolism by 21% (p=0.01)
- •Reduces major bleeding by 31% (p<0.001)
- •Reduces mortality by 11% (p=0.047)

with consistent effects across all major subgroups and with fewer study drug discontinuations on apixaban than on warfarin, consistent with good tolerability.





In patients with atrial fibrillation, apixaban is superior to warfarin at preventing stroke or systemic embolism, causes less bleeding, and results in lower mortality.



THANKS to all investigators and patients



Executive Committee — Christopher B. Granger (cochair), Lars Wallentin (co-chair), John H. Alexander, Jack Ansell, Rafael Diaz, J. Donald Easton, Bernard Gersh, Michael Hanna, John Horowitz, Elaine Hylek, John J.V. McMurray, Puneet Mohan, Freek Verheugt

Steering Committee — Argentina: Rafael Diaz, Cecilia Bahit; Australia: Phil Aylward, John Amerena; Austria: Kurt Huber; Belgium: Jozef Bartunek; Brazil: Alvaro Avezum; Canada: Justin Ezekowitz, Paul Dorian; Chile: Fernando, Lanas; China: Liu Lisheng, Jun Zhu; Colombia: Daniel Isaza; Czech Republic: Petr Jansky; Denmark: Steen Husted; Finland: Veli Pekka Hariola; France: Philippe Gabriel Steg; Germany: Stefan Hohnloser; Hungary: Matyas Keltai; India: Prem Pais, Denis Xavier; Israel: Basil S. Lewis; Italy: Raffaele De Caterina; Japan: Shinya Goto; Mexico: Antonio G. Hermosillo; Netherlands: Antonio M.W. Alings; Norway: Dan Atar; Peru: Luis Segura; Poland: Witold Ruzyllo; Romania: Dragos Vinereanu; Russia: Sergei Varshavsky, S. Golitsyn; South Korea: Byung-Hee Oh; South Africa: Patrick Commerford; Spain: Jose Luis Lopez-Sendon; Sweden: Mårten Rosenqvist; Turkey: Cetin Erol; United Kingdom: John J.V. McMurray; Ukraine: Alex Parkhomenko; United States: Greg Flaker, David Garcia

Data Monitoring Committee — Marc A. Pfeffer (chair), Hans-Christoph Diener, Aldo Pietro Maggioni, Stuart Pocock, Jean-Lucien Rouleau, George Wyse

Duke Clinical Research Institute (DCRI): Lisa Hatch, Missy Banks, Allison Handler, Hongqiu Yang, Jyotsna Garg

PPD: Keven Griffith, Andrew Burr, Tony Dremsizov, Joan Vidal, Sherri Hinton

Bristol-Myers Squibb: Lorraine Rossi, Fred Fiedorek, Sunil Nepal, Robert Croop, Anne Delvaux, Susan Mullin, Natalie Arotsky, Eva Nemeth, Margarida Geraldes, Arnaud Bastien, Robert Wolf

Pfizer: Hubert Pouleur, Neville Jackson, Rogelio Braceras

Clinical Events Committee — John Alexander (chair), Sana Al-Khatib (co-chair), Renato D. Lopes (CEC principal investigator), Claes Held, Elaine Hylek, Cheryl Bushnell, Andreas Terent; Sergio Leonardi, Sumeet Subherwal, Zubin Eapen, John Vavalle, Ali Zomorodi, Bradley Kolls, Jeffrey Berger, Jennifer Vergara, Dipen Parikh, Shams Zia, Greg Stashenko, Carlo Lombardi, Robin Matthews; Emil Hagstrom, Axel Akerblom, Christoph Varenhorst, Shala Ghaderi Berntsson, Anna Stenborg, Erik Lundstrom; Helio Guimaraes, Uri Flato, Salete Nacif, Pedro Barros, Leandro Echenique, Patricia Rodrigues, Luciana Armaganijan, Antonio Carlos Lopes, Alvaro Albrecht.

